Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | CPT1A | P50416 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10436373 | 1.00 | ABCB11 (0.71) | ABCB11LMNAMAPTMAPK1CPT1A | |
| SCHEMBL6260778 | 1.00 | ABCB11 (0.71) | ABCB11LMNAMAPTMAPK1CPT1A | |
| SCHEMBL2477480 | 1.00 | ABCB11 (0.71) | ABCB11LMNAMAPTMAPK1CPT1A | |
| SCHEMBL10436377 | 1.00 | ABCB11 (0.71) | ABCB11LMNAMAPTMAPK1CPT1A | |
| SCHEMBL20338964 | 0.99 | ABCB11 (0.70) | ABCB11LMNAMAPTMAPK1CPT1A | |
| Dechloroetomoxir SCHEMBL6262443 | 0.87 | ABCB11 (0.54) | ABCB11LMNAMAPTMAPK1CYP4F2 | |
| Dechloroetomoxir SCHEMBL10436254 | 0.87 | ABCB11 (0.54) | ABCB11LMNAMAPTMAPK1CYP4F2 | |
| SCHEMBL10436502 | 0.87 | ABCB11 (0.54) | ABCB11LMNAMAPTMAPK1CYP4F2 | |
| SCHEMBL30585170 | 0.86 | ABCB11 (0.68) | ABCB11LMNAMAPTMAPK1CPT1A | |
| SCHEMBL30585168 | 0.86 | ABCB11 (0.68) | ABCB11LMNAMAPTMAPK1CPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110048980-A1 | Fatty Acid Oxidation Inhibitors Treating Hyperglycemia and Related Disorders | SYMCOPEIA COMPANY (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110048980-A1 | Fatty Acid Oxidation Inhibitors Treating Hyperglycemia and Related Disorders | PDE5A, ELOVL5, CPT1B | ABCB11 4665/4885LMNA 1634/4885MAPT 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.